In 1995, Lundbeck opened the Canadian office and began the process of gaining approval to sell Cipramil®, or Celexa® as it is known in Canada. For the first few years in Canada, a small group of employees worked to build awareness of the company. At the time, there were two established Lundbeck products available; Clopixol® and Fluanxol®, both for the treatment of schizophrenia which are still widely used today. The team forged strong, solid relationships with Canadian physicians so that by the time Celexa® (citalpram) received regulatory approval from HealthCanadain 1999, the foundation had been built. The company grew quickly to its current size of over 180 employees.
The company’s long term vision also meant developing Canadian-based clinical research activity with a CNS focus, which continues to grow as Canadian researchers conduct trials with currently available Lundbeck products as well as with innovative treatments that are not yet available in Canada.
1000 rue de la Gauchetière
Ouest Bureau 500
H3B 4W5
Montréal Québec
Canada
Phone +1 514 844 8515
Fax +1 514 844 5495
Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for…
The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…
OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc.…
The CEO of OBIO discusses Ontario’s challenges and opportunities in life sciences, highlighting some of the key initiatives that the organization is taking to help local companies bridge the gap…
Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in…
Warren Shapiro, manager of the North American division of Brunel’s life science sector, offers his insights into Canada’s immense human resources capabilities as well as Brunel’s footprint for contract labor…
Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED…
President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for…
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an…
The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like…
The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded…
The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients,…
Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current…
See our Cookie Privacy Policy Here
